After the approval of the BCL-2 inhibitor venetoclax, the development of BH3 mimetic drugs that target anti-apoptotic BCL-2, BCL-XL, and MCL-1 proteins has been accelerated. For the successful development of candidate drugs, the availability of pharmacodynamic (PD) biomarkers would be important. Pan and colleagues demonstrated that the BH3 profiling, which determines the different ways a cell depends on BCL-2 anti-apoptotic proteins, is a robust and convenient peripheral blood-based PD biomarker for the activity of BH3 mimetics.

A minority of patients with Peripheral T-cell lymphomas (PTCL) present with limited-stage disease and the optimal treatment for this subgroup is unknown. The aim of the nationwide population-based cohort study conducted by Meeuwes and colleagues is to describe first-line treatment and outcome of patients with stage I(E) PTCL identified between 1989 and 2020 in the Netherlands Cancer Registry. They found that for stage I(E) PTCL, the 5-year OS is 59% and a superior outcome is observed in patients treated with chemotherapy combined with radiotherapy.